Navigation Links
ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update
Date:8/11/2008

une 30, 2008, compared to a net loss of $5.7 million, or $0.06 per share, for the same period in 2007. Included in the net loss for the three-month period ended June 30, 2008 were non-cash, share-based compensation expenses amounting to $0.4 million, compared to $0.6 million for the same period in 2007.

In May 2008, the Company settled its dispute with Theragenex. In consideration of and conditioned upon Theragenex paying the Company $0.6 million, the parties agreed to jointly move to dismiss the underlying arbitration action, and in connection with dismissing the arbitration, agreed to release each other from any and all claims related to their past relationship, including Theragenex's rights under their prior agreement. For the three-month period ended June 30, 2008, the Company recognized $0.5 million in licensing revenue, which represents a portion of the $0.6 million Theragenex settlement payment. The additional $0.1 million was recognized as other income.

Research and development, or R&D, expenses increased by $0.3 million, or 6%, to $4.5 million for the three-month period ended June 30, 2008, from $4.2 million for the same period a year ago. The increase was primarily due to a $1.3 million increase in expenses related to external research-related manufacturing and regulatory and quality assurance activities related to ANX-530 and ANX-514, offset by a $0.8 million decrease in external clinical trial expenses related to ANX-530 and ANX-510, or CoFactor, a decrease of $0.1 million personnel and related costs and a $0.1 million decrease in share-based compensation expense. R&D expenses for the three-month period ended June 30, 2008 included non-cash, share-based compensation expense amounting to $0.1 million, compared to $0.2 million for the same period a year ago.

Selling, general and administrative, or SG&A, expenses increased by $0.6 million, or 31%, to $2.6 million for the three-month period ended June 30, 2008, from $2.0 million for the
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results
2. ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference
3. ADVENTRX Pharmaceuticals to Present at the 2007 RBC Capital Markets Healthcare Conference
4. ADVENTRX Pharmaceuticals to Present at the 13th Annual BIO-Europe Partnering Conference
5. ADVENTRX Pharmaceuticals to Present at the 18th Annual CIBC Healthcare Conference
6. Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
7. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
8. Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
9. Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
10. Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
11. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... IN (PRWEB) October 20, 2014 ... Start, a secure cloud solution that enables healthcare ... of the ultimate healthcare-specific customer relationship management (“CRM”) ... meet the unique needs of the healthcare industry, ... experience for providers and patients by combining healthcare ...
(Date:10/20/2014)... October 20, 2014 JZ Fitness, an ... coaching, corporate wellness programming, authorship, international lecturing and community ... to announce the release of the JZ Fitness nutrition ... years of coaching thousands of individuals on nutrition, Jenn ... that does not require calorie counting or cumbersome food ...
(Date:10/20/2014)... Principle Business Enterprises, a family owned ... top-of-the-line absorbent products. The company has recently made ... brand, Tranquility® Premium Protection absorbent products. The company ... its packaging a new look, and is currently working ... the public. , The new website, developed with Thread ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Voicheck as Assistant Director of their CentralSource ... in managing the innovative turnkey drug sourcing, distribution, ... Matthew brings over 12 years of industry experience, ... Myoderm at the peak of their international success ...
(Date:10/20/2014)... Portland, Oregon (PRWEB) October 20, 2014 Succeed ... 16% of local companies who participated in the Every ... Walk! is a public awareness project that encourages workers to ... the Summer Step 10,000 Program, which concluded at the end ... wide variety of cities and metro areas. Participating companies ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2
... by menopausal women causes a type of ovarian cancer to ... researchers at the University of Colorado Cancer Center. Menopausal ... the cancer metastasizing to the lymph nodes, according to the ... of Cancer Research . The study was released online ...
... 20 (HealthDay News) -- A combination of animal and human ... that could ultimately help in the treatment of major depression, ... of a brain protein known as p11. The study authors ... feelings of reward, pleasure and satisfaction with positive life experiences. ...
... black rice a little-known variety of the grain that ... may help soothe the inflammation involved in allergies, asthma, ... Journal of Agricultural and Food Chemistry . Mendel Friedman ... potential health benefits of eating black rice bran. Bran is ...
... -- Scientists have identified common genetic variations that may explain ... E is an antioxidant found in a number of oils, ... peppers, tomatoes and pumpkins. Previous research has found that vitamin ... vitamin in a person,s body. It,s been suspected that this ...
... , WEDNESDAY, Oct. 20 (HealthDay News) -- People ... for potentially serious eye damage, says a small new study ... which is located near the center of the retina at ... detailed central vision and the processing of light. In ...
... , TUESDAY, Oct. 19 (HealthDay News) -- Men ... premature death from heart disease and all causes, a finding ... factor for cardiovascular disease, according to new research. The ... followed-up for about seven years. At the start of the ...
Cached Medicine News:Health News:Estrogen replacement therapy speeds ovarian cancer growth, new study reports 2Health News:Animal Study Explores Potential Gene Therapy for Depression 2Health News:Animal Study Explores Potential Gene Therapy for Depression 3Health News:People With Anorexia May Risk Serious Eye Damage 2Health News:Low Testosterone May Raise Risk of Early Death: Study 2
(Date:10/20/2014)... de octubre de 2014  PneumRx, Inc. ( ... la pulmonología intervencional, anunció hoy la conclusión de ... meses antes de lo programado. El Estudio Clínico RENEW ... de investigación (IDE) aprobada por la FDA (Administración ... espiral de reducción de volumen pulmonar PneumRx RePneu, ...
(Date:10/20/2014)... Oct. 20, 2014 Valeritas, Inc., a leader ... patients with Type 2 diabetes, announced today that it ... Award. The award was presented October 16 th ... Columbus, Ohio . The Cardinal ... a variety of metrics specifically targeted at the importance ...
(Date:10/20/2014)... 2014 Lpath, Inc. (NASDAQ: ... therapeutics, received official notification from the European Patent Office ... patent supporting its iSONEP™ and ASONEP™ programs. ... No. 2087002, claims compositions of matter related to ... compounds, iSONEP and ASONEP. Sonepcizumab is an antibody ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... Mich., Jan. 9, 2012  Diplomat Specialty Pharmacy, the nation,s ... today it has received limited distribution rights from ... On November 18, 2011, EYLEA ... Drug Administration and is indicated for the treatment ...
... Calif., Jan. 9, 2012 Uptake Medical ® ... C funding round. The round was led by Singapore-based ... Ventures, GBS Venture Partners, WRF Capital, Arboretum Ventures and ... managing partner, will join the Uptake Medical board of ...
Cached Medicine Technology:Diplomat Specialty Pharmacy to Provide Specialty Pharmacy Services for EYLEA™ (aflibercept) Injection 2Uptake Medical Announces Successful Completion of Series C Financing 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: